{"id":"NCT01741701","sponsor":"University of Kansas Medical Center","briefTitle":"A Pilot Study of Oxaloacetate in Subjects With Treated PD","officialTitle":"A Pilot Double-Blind, Parallel Group, Placebo Controlled Study of Oxaloacetate in Subjects With Treated Parkinson's Disease (PD)","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2012-12","primaryCompletion":"2014-10","completion":"2014-10","firstPosted":"2012-12-05","resultsPosted":"2016-03-17","lastUpdate":"2016-03-17"},"enrollment":33,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Parkinson's Disease"],"interventions":[{"type":"DRUG","name":"Oxaloacetate (OAA)","otherNames":["benaGeneâ„¢"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Oxaloacetate (OAA)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine if Oxaloacetate (OAA) is a safe and effective treatment for Parkinson's disease. Each subject will be asked to make 3 study visits and complete two safety follow-up phone calls over a 4 month period.","primaryOutcome":{"measure":"Unified Parkinson's Disease Rating Scale (UPDRS) Total Score","timeFrame":"4 months","effectByArm":[{"arm":"Oxaloacetate (OAA)","deltaMin":41.1,"sd":6.7},{"arm":"Placebo","deltaMin":42.9,"sd":10.8}],"pValues":[{"comp":"OG000 vs OG001","p":"0.50"}]},"eligibility":{"minAge":"30 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":18},"commonTop":["Worsening of Parkinson's disease","insomnia/stimulant","GI upset","Fatigue","Cognitive worsening"]}}